在慢性阻塞性肺病中,LAMA-LABA吸入器的比较有效性和安全性
Gerard T Portela1,2, Shirley V Wang1,2, Samy Suissa3
1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
JAMA internal medicine
|February 23, 2026
概括
在COPD恶化方面,umeclidinium-vilanterol干粉吸入器与糖烯酸甲醇和铁烯酸醇相比,显示出更好的结局. 这些发现表明,对于开始长效肌肉抗剂-长效β2agonist治疗的患者来说,可能会有潜在的益处.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 长效肌抗体 (LAMA) 和长效β2抗体 (LABA) 双重支气管扩展剂治疗建议用于症状慢性阻塞性肺病 (COPD).
- 固定剂量LAMA-LABA吸入器可提供各种设备类型,包括干粉,计量剂量和软雾吸入器.
- 对于计量剂量吸入器的温室气体排放存在担忧,以及因活性成分,剂量和设备的变化而导致LAMA-LABA疗法的有效性可能存在差异.
研究的目的:
- 为了比较每天一次使用的umeclidinium-vilanterol干粉吸入器,每天两次使用的glycopyrrolate-formoterol计量剂量吸入器和每天一次使用的tiotropium-olodaterol软雾吸入器的有效性和安全性.
- 为了评估第一次中度或重度COPD恶化,主要心血管不良事件,尿路感染和肺炎住院的时间.
主要方法:
- 一项观察性,活性-比较研究分析了新接受LAMA-LABA吸入器治疗的患者 (≥40岁) 的索赔数据.
- 倾向性得分匹配用于创建1:1队列进行比较.
- 该研究包括了连续注册医疗保险或医疗保险优势计划的患者,分析了从2016年5月到2025年2月的数据.
主要成果:
- 与糖烯酸甲醇相比,乌梅克利迪尼-维兰特醇与COPD恶化的风险降低了14% (HR,0.86;NNT,17).
- 与tiotropium-olodaterol相比,umeclidinium-vilanterol显示了COPD恶化的风险降低了3% (HR,0.97;NNT,100).与tiotropium-olodaterol相比,umeclidinium-vilanterol显示了COPD恶化的风险降低了3% (HR,0.97;NNT,100).与tiotropium-olodaterol相比,umeclidinium-vilanterol显示了COPD恶化的风险降低了3% (HR,0.97;NNT,100).
- 蒂奥特罗-奥洛达特醇显示,COPD恶化的危险性比甘氨酸甲基醇 (HR,0.94) 低6%. 在所有队伍中观察到心血管事件,尿道感染和肺炎的风险相似.
结论:
- 每天一次使用umeclidinium-vilanterol干粉吸入器,与glycopyrrolate-formoterol和tiotropium-olodaterol相比,改善了临床结果,特别是减少了COPD恶化.
- 这些发现表明,umeclidinium-vilanterol可能是LAMA-LABA治疗新用户的首选选择.
- 患者,处方医生和卫生系统在选择LAMA-LABA吸入器时可以考虑这些比较有效性数据.
更多相关视频
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
10.6K
04:24Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
1.2K
相关概念视频
01:23Inhaled Medications
889
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
889
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.8K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.8K
01:26COPD: Management Using Bronchodilators and Corticosteroids
907
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
907
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.2K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.2K